Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Fuller

Showing results (101-110 of 102) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 102 results.
Journal of Medicinal Chemistry|February 9, 2026
Discovery of EGT710, an Oral Nonpeptidomimetic Reversible Covalent SARS-CoV-2 Main Protease InhibitorJulien P N Papillon, Jun Yuan, Matthew J Hesse, et al.
Npj Drug Discovery|July 1, 2026
Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitorStephanie A Moquin, Suresh B Lakshminarayana, Kamal Kumar Balavenkatraman, et al.
Pageof 11

Showing results (101-110 of 102) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 102 results.
Journal of Medicinal Chemistry|February 9, 2026
Discovery of EGT710, an Oral Nonpeptidomimetic Reversible Covalent SARS-CoV-2 Main Protease InhibitorJulien P N Papillon, Jun Yuan, Matthew J Hesse, et al.
Npj Drug Discovery|July 1, 2026
Preclinical characterization of EGT710, an oral non-peptidomimetic reversible covalent SARS-CoV-2 main protease inhibitorStephanie A Moquin, Suresh B Lakshminarayana, Kamal Kumar Balavenkatraman, et al.
Pageof 11